Asarfi Hospital Ltd

Asarfi Hospital Ltd

Asarfi Hospital Ltd has announced that CRISIL Ratings Limited has upgraded the credit rating of the bank facilities of Asarfi Hospital Limited to CRISIL BBB/Stable and CRISIL A3+ for bank debt, with a rated amount enhanced to ₹60 Crore.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half-year ended September 30, 2026.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has submitted the consolidated voting results of its 21st AGM, held on September 18, 2026, along with the scrutinizer's report on remote e-voting and voting at the AGM. The results will be available on the company's website.

Asarfi Hospital Ltd

Asarfi Hospital Ltd held its 21st Annual General Meeting (AGM) on September 18, 2026, where the company's audited standalone and consolidated financial statements for the year ended March 31, 2026, were approved. The meeting also approved the appointment of Gopal Singh as a director and the migration of the company's listing from the BSE SME platform to the BSE main board.

Asarfi Hospital Ltd

Asarfi Hospital Ltd held its Board Meeting on August 25, 2026, approving several matters including re-appointment of a Director, convening the 21st AGM on September 18, 2026, and migration to BSE Main Board and proposed listing on NSE.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has scheduled its 4th Board Meeting for FY 2026-27 on August 25, 2026, to consider and approve various agenda items, including the re-appointment of a director, appointment of a cost auditor, and migration from the BSE SME Platform to the BSE Main Board and listing on NSE.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing revenue growth of 33% YoY to Rs 4,734 lakhs, with EBITDA margin at 20% and PAT margin at 9%, driven by better realizations, improved ARPOB, and enhanced case mix across both hospital units.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, showing a 33% YoY revenue growth to ₹4,734 Lakhs, with EBITDA margin at 20% and PAT margin at 9%. The company's operational momentum across units is driven by growth in patient volumes and higher realizations, with ARPOB increased to ₹23,498 (Super-Specialty) and ₹31,892 (Cancer Unit).

Asarfi Hospital Ltd

Asarfi Hospital Ltd has released its Q1 FY27 investor presentation, showing revenue growth of 32.8% YoY to ₹4,734 Cr, EBITDA growth of 33.9% YoY to ₹942 Cr, and PAT growth of 33.5% YoY to ₹427 Cr. The company's occupancy rate has improved to 59% in Q1 FY27, with a bed capacity of 285 and ARPOB of 23,498.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has submitted its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, with the board of directors approving the results at a meeting held on 07 August 2026. The results include a standalone unaudited balance sheet as at 30 June 2026, showing a total of ₹10,278.23 in equity and liabilities, with a significant increase in long-term borrowings and deferred tax liabilities.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has submitted its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, which were approved by the Board of Directors on 07 August 2026. The results include unaudited standalone financial results, unaudited consolidated financial results, and limited review reports from the statutory auditors.

Asarfi Hospital Ltd

Asarfi Hospital Ltd has scheduled a board meeting on 07/08/2026 to consider and approve the unaudited financial results for the quarter ended 30th June, 2026, along with the limited review report issued by the statutory auditors.

Asarfi Hospital Ltd

Asarfi Hospital Ltd participated in an Analyst/Investor Webinar on 24 July 2026, discussing its business operations, financial performance, strategic initiatives, and future growth prospects. The Company highlighted its consistent financial performance, expansion of its oncology business, and proposed establishment of a 100-seat Medical College under the Public-Private Partnership model.